<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9956">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05686720</url>
  </required_header>
  <id_info>
    <org_study_id>PCZCTP-220702-001</org_study_id>
    <nct_id>NCT05686720</nct_id>
  </id_info>
  <brief_title>Single-arm, Open-label Clinical Study of SZ011 in the Treatment of Advanced Triple Negative Breast Cancer</brief_title>
  <official_title>Single-arm, Open-label Clinical Study of SZ011 in the Treatment of Advanced Triple Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital of Shantou University Medical College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guangdong ProCapZoom Biosciences Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>First Affiliated Hospital of Shantou University Medical College</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was a single-center, open-label, investigator-initiated clinical trial (IIT) to&#xD;
      observe and investigate the clinical safety and efficacy of SZ011 in the treatment of&#xD;
      advanced triple-negative breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2023</start_date>
  <completion_date type="Anticipated">June 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2024</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Events (AEs)</measure>
    <time_frame>Up to 6 months after infusion</time_frame>
    <description>To evaluate the safety of SZ011 CAR-NK Cells</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Up to 6 months after infusion</time_frame>
    <description>To evaluate the ORR of SZ011 CAR-NK Cells</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 6 months after infusion</time_frame>
    <description>To determine the anti-tumor effectivity of SZ011 CAR-NK Cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Up to 6 months after infusion</time_frame>
    <description>To determine the anti-tumor effectivity of SZ011 CAR-NK Cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to 6 months after infusion</time_frame>
    <description>To determine the anti-tumor effectivity of SZ011 CAR-NK Cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of remission (DOR)</measure>
    <time_frame>Up to 6 months after infusion</time_frame>
    <description>To determine the anti-tumor effectivity of SZ011 CAR-NK Cells</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Advanced Triple Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>SZ011 CAR-NK</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SZ011 CAR-NK</intervention_name>
    <description>In the escalation study, the minimum initial dose was 5.0×10^6 cells, then increased to 5.0×10^7 and 2.0×10^8 cells. The infusion is given every 2 weeks.</description>
    <arm_group_label>SZ011 CAR-NK</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients voluntarily join the study, sign the informed consent form, and have&#xD;
             willingness and ability to comply with study procedures.&#xD;
&#xD;
          2. Female ≥ 18 years.&#xD;
&#xD;
          3. Histologically confirmed advanced TNBC , namely, human epidermal growth receptor&#xD;
             2-negative (HER2-negative) and estrogen receptor-negative (ER-negative) and&#xD;
             progesterone receptor-negative (PR-negative).&#xD;
&#xD;
          4. The tumor tissue shows positive mesothelin (MESO) detected by immunohistochemistry.&#xD;
&#xD;
          5. At least one target lesion that can be stably evaluated at baseline as per the solid&#xD;
             tumor efficacy evaluation criteria (RECIST v1.1).&#xD;
&#xD;
          6. Progress after receiving second-line or above treatment in the past.&#xD;
&#xD;
          7. Eastern Cooperative Oncology Group (ECOG) performance status: 0-2 points.&#xD;
&#xD;
          8. Estimated survival time ≥ 12 weeks.&#xD;
&#xD;
          9. Important organ function meets the following requirements:&#xD;
&#xD;
               1. Blood routine test: neutrophil count (ANC) ≥1.5 × 109/L; Lymphocyte count (LC)&#xD;
                  ≥0.5×109/L; Platelet count (PLT) ≥75 × 109/L; Hemoglobin (HG) ≥ 90 g/L;&#xD;
&#xD;
               2. Blood biochemistry test:&#xD;
&#xD;
             Liver functions: alanine aminotransferase (ALT) and aspartate aminotransferase (AST)&#xD;
             ≤2.5×ULN, alkaline phosphatase (ALP)&#xD;
&#xD;
               -  2.5×ULN, total bilirubin (TBIL) ≤1.5×ULN; except in the following cases:For&#xD;
                  patients with liver metastasis: AST and/or ALT ≤5×ULN, TBIL&#xD;
&#xD;
               -  3×ULN; For patients with liver or bone metastasis: ALP≤5×ULN; Renal function: BUN&#xD;
                  and Cr ≤1.5×ULN and creatinine clearance ≥60 mL/min (Cockcroft-Gault formula).&#xD;
&#xD;
         10. Women of childbearing potential must have a serum pregnancy test performed 7 days&#xD;
             before the first dose and be assessed as non-pregnant. Female subjects of childbearing&#xD;
             potential must agree to use an efficient method of contraception (e.g., an&#xD;
             intrauterine device, contraceptive pill, or condom) within 4 weeks from the date of&#xD;
             the informed consent form until the last dose of study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The patient had other malignancies within the 5 years prior to screening, in addition&#xD;
             to cured cervical carcinoma in situ, basal or squamous cell skin cancer, and&#xD;
             postoperative ductal carcinoma in situ.&#xD;
&#xD;
          2. Patients with active (without medical control or with clinical symptoms) brain&#xD;
             metastasis, cancerous meningitis, spinal cord compression, or patients with a history&#xD;
             of primary tumors of the central nervous system.&#xD;
&#xD;
          3. The patient with moderate to large amount of pleural effusion, intraperitoneal&#xD;
             effusion or pericardial effusion that cannot be controlled and need repeated drainage.&#xD;
&#xD;
          4. Patients with uncontrolled tumor-related pain judged by the researcher. Subjects in&#xD;
             need of analgesic therapy must have a stable analgesic regimen in place by study&#xD;
             entry. Symptomatic lesions suitable for palliative radiotherapy should be treated&#xD;
             before entering the study.&#xD;
&#xD;
          5. The patient has other active virus and bacterial infection with significant clinical&#xD;
             significance or systemic fungal infection that cannot be controlled.&#xD;
&#xD;
          6. Anyone who has had arterial thromboembolism events (including myocardial infarction,&#xD;
             cardiac arrest, cerebrovascular accident, cerebral ischemia, and a history of deep&#xD;
             vein thrombosis or pulmonary embolism of Class 3 or above by CTCAE5.0) within six&#xD;
             months before enrollment.&#xD;
&#xD;
          7. Patients with a history of severe hemorrhagic disease within 6 months before&#xD;
             enrollment, or those who were considered by the investigator to have a clear bleeding&#xD;
             tendency (such as esophageal varices at risk for bleeding, locally active ulcer&#xD;
             lesions, and fecal occult blood &gt; 2+).&#xD;
&#xD;
          8. Anyone who is diagnosed with congenital or acquired immunodeficiency (such as&#xD;
             HIV-infected), or active hepatitis (HBV, HCV) infection, or other serious infectious&#xD;
             diseases.&#xD;
&#xD;
          9. With clinically significant cardiovascular disease: a) uncontrollable hypertension&#xD;
             after treatment (systolic blood pressure ≥160mmHg and/ or diastolic blood pressure&#xD;
             ≥110 mmHg); b) Has a history of myocardial infarction or unstable angina within 6&#xD;
             months before enrollment; c) Congestive heart failure or grade II heart failure; d)&#xD;
             Arrhythmia in serious need of medical treatment, excluding asymptomatic atrial&#xD;
             fibrillation with controllable heart rate.&#xD;
&#xD;
         10. Patients with a history of allergy to any component of cell products.&#xD;
&#xD;
         11. Anyone who has participated in or is participating in other clinical trials within&#xD;
             three months.&#xD;
&#xD;
         12. Pregnant or lactating women.&#xD;
&#xD;
         13. Anyone who was considered by the investigator to be unsuitable to participate in this&#xD;
             clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jing Lin, PhD</last_name>
    <phone>13531285809</phone>
    <email>316603568@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shantou</name>
      <address>
        <city>Shantou</city>
        <zip>GuangDong</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>December 22, 2022</study_first_submitted>
  <study_first_submitted_qc>January 9, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2023</study_first_posted>
  <last_update_submitted>January 9, 2023</last_update_submitted>
  <last_update_submitted_qc>January 9, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital of Shantou University Medical College</investigator_affiliation>
    <investigator_full_name>Jing Lin</investigator_full_name>
    <investigator_title>Deputy Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

